TPBG/5T4, His, Cynomolgus

TPBG/5T4, His, Cynomolgus

The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs.
Z04930
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
TPBG/5T4 (Thr35-Ser355)
Accession # Q4R8Y9		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized TPBG/5T4, His, Cynomolgus at 0.5μg/ml (100μl/Well) on the plate can bind Anti­TPBG Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 35.95 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs.
Synonyms M6P1; 5T4AG; WAIF1; TPBG; 5T4

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.